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Abstract
Introduction: Diabetic foot is a diabetes mellitus complication leading to recurrent ulcerations, risk of osteomyelitis and tissue necrosis 
which may finally result in amputation. Diabetic foot of neuropathic origin manifesting as autonomic and sensory motor neuropathy is 
the most common type of this complication. The aim of this study was to identify risk factors of diabetic foot of neuropathic origin oc-
currence in patients with type 2 diabetes.
Material and methods: The study included 240 patients, 74 with diabetic foot of neuropathic origin and 166 with diabetes. Cases and 
controls were matched in terms of age structure. Patients with peripheral arterial disease were excluded from the study. The study was 
conducted in the Gastroenterology and Metabolic Diseases Department, Medical University of Warsaw, Poland. We used logistic regres-
sion models, χ2, U Mann-Whitney’s and t-Student tests. 
Results: Logistic regression analysis showed that diabetic foot of neuropathic origin risk factors were: male gender (OR = 6.63; 95% 
CI: 3.31–13.27; p = 0.00001), duration of diabetes (OR = 1.10; 95% CI: 1.06–1.14; p = 0.00001), height (OR = 1.09; 95% CI: 1.06–1.13; 
p = 0.00001), weight (OR = 1.04; 95% CI: 1.04–1.06; p = 0.00001) and waist circumference (OR = 1.05; 95% CI: 1.02–1.08; p = 0.001). 
Although there was a correlation between diabetic foot of neuropathic origin and BMI value, it had no impact on DF occurrence risk.
Conclusion: It is possible to identify patients at risk of diabetic foot development by evaluating anthropometric features. The existence 
of specific factors increasing the odds of diabetic foot of neuropathic origin occurring may lead to the identification of patients at risk of 
its development. (Endokrynol Pol 2015; 66 (1): 10–14)
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Streszczenie
Wstęp: Zespół stopy cukrzycowej jest powikłaniem cukrzycy prowadzącym do powstania nawracających owrzodzeń, ryzyka zapalenia 
kości i szpiku kostnego, a ostatecznie martwicy tkanek wymagającej amputacji kończyny dolnej. Zespół stopy cukrzycowej o etiologii 
neuropatycznej jest najczęstszym rodzajem tego powikłania, w którym dominują objawy neuropatii autonomicznej i czuciowo-ruchowej. 
Celem pracy była ocena czynników ryzyka neuropatycznego zespołu stopy cukrzycowej u chorych z cukrzycą typu 2.
Materiał i metody: Do badania włączono 240 osób, 74 chorych z zespołem stopy cukrzycowej typu neuropatycznego oraz 166 chorych 
z cukrzycą typu 2 bez zespołu stopy cukrzycowej. Grupę badaną i kontrolną dobrano pod względem struktury wieku. Chorych z cho-
robą naczyń obwodowych wyłączono z badania. Badanie przeprowadzono w Katedrze i Klinice Gastroenterologii i Chorób Przemiany 
Materii Warszawskiego Uniwersytetu Medycznego. Użyto modelu regresji logistycznej oraz testów: χ2, U Mann-Whitneya i t-Studenta. 
Wyniki: Analiza regresji logistycznej wykazała, że czynnikami ryzyka neuropatycznego zespołu stopy cukrzycowej były płeć męska 
(OR = 6,63; 95% CI: 3,31–13,27; p = 0,00001), czas trwania cukrzycy (OR = 1,10; 95% CI: 1,06–1,14; p = 0,00001), wzrost (OR = 1,09; 95% 
CI: 1,06–1,13; p = 0,00001), masa ciała (OR = 1,04; 95% CI: 1,04–1,06; p = 0,00001) i obwód talii (OR = 1,05; 95% CI: 1,02–1,08; p = 0,001). 
Zaobserwowano również korelację między neuropatycznym zespołem stopy cukrzycowej a wartością BMI, która nie miała wpływu na 
ryzyko wystąpienia zespołu stopy cukrzycowej (p = 0,01). 
Wnioski: Istnienie specyficznych czynników zwiększających ryzyko wystąpienia neuropatycznego zespołu stopy cukrzycowej może się 
przyczynić do wyłonienie grupy chorych, którzy mogliby odnieść największą korzyść z objęcia długoterminową opieką w warunkach 
specjalistycznej opieki zdrowotnej. Wczesna identyfikacja takich chorych może zmniejszyć ryzyko wielomiesięcznego gojenia owrzodzeń, 
a także amputacji kończyn dolnych. (Endokrynol Pol 2015; 66 (1): 10–14)
Słowa kluczowe: neuropatyczny zespół stopy cukrzycowej; cukrzyca; ryzyko
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total cost of DM and its complications treatment in the 
United States ranges between 4.6 and 13.7 billion dollars 
[15]. As much as 27% of such costs may be spent on the 
management of neuropathy and DF.
The aim of this study was to identify factors increas-
ing the risk of DF of neuropathic origin in patients with 
type 2 DM. The rationale for the study was clinically 
observed differences between patients with DF of neu-
ropathic origin and patients with DF of ischaemic or 
mixed aetiology. There have been a few studies compar-
ing groups of patients with DF of neuropathic origin 
to patients with type 2 DM with no clinical history of 
ulcerations or neuropathy. The available studies are 
either based on small study groups or focused only on 
risk factors of neuropathy [12, 13, 16–24]. 
Material and methods
This study was conducted in the Gastroenterology 
and Metabolic Diseases Department and Department 
of Medical Genetics, Medical University of Warsaw, 
Poland. The study involved 240 individuals. The study 
group consisted of 74 patients with type 2 DM and DF 
of neuropathic origin, and 166 patients with type 2 DM 
without a history of foot ulcerations as a control group. 
The control group was matched to cases in terms of age 
structure. Patients with peripheral arterial disease were 
excluded from the study. A questionnaire was used in 
the assessment of DF presence according to the criteria 
of the International Consensus on the Diabetic Foot and 
Practical Guidelines [5]. 
DF was defined as ulceration, infection or damage of 
deep tissues in the foot below the ankle in a patient with 
DM and the presence of neuropathy and/or peripheral 
arterial disease according to the International Consensus 
on the DF and Practical Guidelines [2]. Neuropathy was 
diagnosed in patients who achieved more than six points 
in examination according to the Toronto Clinical Neuropa-
thy Scale [25]. When a painless ulceration was present, 
a DF of neuropathic origin was diagnosed. Foot tissue 
wounds were assessed in the University of Texas Clas-
sification [26]. Neuropathy was assessed using standard 
tests confirming the presence of neuropathy if the sense 
of touch with a 10-g monofilament of Semmes-Weinstein 
was absent in at least two of the three places identified 
by the International DF Consensus [27]. Other tests were 
used to assess neuropathy (sense of temperature due to 
Thermo-Tip, vibration due to Rydel-Seiffer tuning fork, 
and neurothesiometer). Assessment of arterial blood flow 
was performed in clinical examination (the presence of 
pulse on dorsal pedis and tibial posterior arteries) con-
firmed due to routinely assessed Ankle Brachial Index and 
Ultrasound Doppler of lower limbs arteries. Patients with 
previously performed revascularisation had angiography 
Introduction
A diabetic foot is the most common complication of 
long-lasting diabetes mellitus (DM) [1–3]. Diabetic foot 
(DF) occurs in approximately 12–25% of patients with 
DM type 2 [4]. According to the International Consensus 
on the DF and Practical Guidelines, DF may occur in the 
form of ulceration, inflammation and/or deep foot tissues 
lesions located below the ankle in patients with DM [5]. 
The presence of sensory deficiency and angiopathy may 
result in foot ulcerations and delayed wound healing.
Neuropathy is one of the most important factors 
in the aetiopathogenesis of DF that increases its risk 
by 1.7 fold [6]. Neuropathy is a cause of 50–75% of 
non-traumatic amputations in developed countries [7]. 
Neuropathy often coexists with foot deformation and 
recurrent ulcerations that increase the risk of death by 
12- and 36-fold respectively [8]. Patients who undergo a 
lower limb amputation (LLA) due to the complications 
of long-lasting DM are at 50% risk of a second amputa-
tion within 3–5 years [9]. The five-year death risk in this 
group is 50% [9]. Neuropathy is also the most impor-
tant factor affecting DF recurrence. The recurrence is 
much more frequent in the first three years after LLA 
and reaches up to 50% [1]. Neuropathy in diabetic pa-
tients is often asymptomatic and may affect as many as 
80–90% of patients at different stages of diabetes [10]. 
In patients diagnosed with DM type 2, neuropathy is 
often present at the moment of diagnosis, whereas in 
patients with DM type 1, it may appear as much as five 
years after diagnosis [11]. 
Patients diagnosed with DF of neuropathic origin 
have a much better prognosis of complete wound heal-
ing compared to DF of ischaemic or mixed origin [12]. 
They have also a lower risk of recurrence, shorter dura-
tion of treatment, lower risk of toe or foot amputation, 
and a likely lower death ratio [12]. Usually, patients are 
diagnosed with DF at a very advanced stage of inflam-
mation [13]. This results in a high amputation rate in 
this group. To prevent amputation in DF patients, it is 
critical to assess the risk of its occurrence. 
The identification of factors that increase the risk of 
DF of neuropathic origin in patients with type 2 DM 
may result in the improved care of patients prone to its 
development. Improved care may result in a decrease in 
the frequency of DM complications, decrease in pace of 
complications advance, or lower patient and/or budget 
costs spend on their treatment. The Elbert et al. study 
conducted in the United States showed that in the coming 
25 years, the number of patients with DM will double and 
the total costs of DM treatment will increase [14]. Without 
modifications in individual and global approaches to DM 
and its complications management, the healthcare budget 
burden will increase dramatically. It is estimated that the 
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of arteries of lower limbs. Patients included into the study 
were in the acute or chronic stages of DF, and it was their 
first or recurrent ulceration.
The statistical calculations were performed using 
STATISTICA 10PL (StatSoft Inc. 2011) software. In as-
sessment of qualitative variables, a χ2 test was used. 
In assessment of quantitative predictors for normal 
and not normal distribution of variables, a t-Student 
and U Mann-Whitney’s tests were used respectively. 
A univariate logistic regression was performed for 
quantitative predictors and grouping variables when 
a statistical significance was present. The univariate 
logistic regression analysis was performed with an 
online ‘Logistic Regression by John C. Pezzullo, Version 
05.07.20’ (http://statpages.org/logistic.html) program. 
The statistical significance level was α = 0.05. In statisti-
cal analysis, missing data was removed in pairs.
Results
There were no differences in age of the individuals 
between groups (61 ± 10 years v 63 ± 8 years; p = 0.1). 
In the study group, the mean time between type 2 DM 
diagnosis and first occurring DF of neuropathic origin 
was eight years; SD = 8. There was no significant dif-
ference between the mean time from DM diagnosis to 
DF occurrence in cases and the mean duration of type 
2 DM in controls (mean 8 ± 8 years vs. 10 ± 8 years; 
p = 0.06). Characteristics of studied groups are pre-
sented in Table I. Characteristics of clinical complica-
tions are presented in Table II. 
In logistic regression model, male gender was an im-
portant factor increasing the risk of DF of neuropathic ori-
gin development in patients with type 2 DM (OR = 6.63; 
95% CI: 3.31–13.27; p = 0.00001) (Fig. 1., Table III).
Factors that increase the risk of DF of neuropathic 
origin occurrence were: duration of DM (mean 17 ± 8 
years vs. 10 ± 8 years; OR = 1.10; 95% CI: 1.06–1.14; 
p = 0.00001) increasing odds of DF by 10% per each year of 
DM duration; height (mean 174 ± 8 cm vs. 166 ± 10 cm; 
OR = 1.09; 95% CI: 1.06–1.13; p = 0.00001) increasing this 
risk by 9% per each cm of patient’s height; weight (mean 
96 ± 17 kg vs. 83 ± 18 kg; OR = 1.04; 95% CI: 1.04–1.06; 
p = 0.00001) that has an impact of 4% increase in the 
risk of DF per each additional kg; and waist circumfer-
ence (mean 114 ± 14 cm vs. 104 ± 15 cm; OR = 1.05; 
Table I. Characteristics of studied groups
Tabela I. Charakterystyka badanych grup
Group Diabetic foot of neuropathic origin Diabetes mellitus type 2 p value
Total number 74 166 –
Women/men (%) 17/83 58/42 0.00001
Mean age (years) 61 ± 10 63 ± 8 0.1
Mean diabetes duration (years) 17 ± 8 10 ± 8 0.00001
Mean height [cm] 174 ± 8 166 ± 10 0.00001
Mean weight [kg] 96 ± 17 83 ± 18 0.00001
Mean body mass index [kg/m2] 32 ± 5.4 30.4 ± 5.6 0.06
Waist circumference [cm] 114 ± 14 104 ± 15 0.001
Hip circumference [cm] 112 ± 12 108 ± 13 0.1
Table II. Characteristics of clinical complications present in studied groups
Tabela II. Charakterystyka powikłań obecnych w badanych grupach
Diabetic foot of neuropathic origin n = 74 Type 2 diabetes mellitus n = 166 p value
Overweight, BMI > 24.9 kg/m2 59/66 139/162 0.5
Hyperlipidaemia 29/67 93/158 0.03
Hypertension 49/62 100/124 0.8
Ischaemic heart disease 27/69 43/153 0.1
Myocardial infarction 22/68 35/151 0.1
Thromboembolic events 12/64 12/154 0.02
Retinopathy 43/69 29/165 0.00001
Nephropathy 20/70 9/155 0.00001
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95% CI: 1.02–1.08; p = 0.001) increasing odds by 5% for 
each extra cm in waist. Similarly, the presented study 
showed a positive correlation between BMI value and 
DF of neuropathic origin frequency; however, it had 
no impact on its occurrence risk. There was no differ-
ence in hips circumference value between the groups. 
In the study group, thromboembolic events (18% vs. 
8%; p = 0.02), retinopathy (62% vs. 18%; p = 0.00001) 
and nephropathy (29% vs. 6%; p = 0.00001) were more 
often present. Hyperlipidaemia was less often present 
in the study group (43% vs. 61%; p = 0.03) (Fig. 2). 
Retinopathy, nephropathy and hyperlipidaemia were 
assessed only as qualitative variables. There were no 
differences in the frequency of overweight, hyperten-
sion, ischaemic heart disease and myocardial infarction 
between the groups.
Discussion
The strengths of the presented study are relatively 
large study and control groups, no differences in age 
structure of studied groups, detailed anthropometric 
and clinical features descriptions, and a neuropathy 
classification based on clear criteria according to the 
Toronto Clinical Neuropathy Scale. 
The limitations of the presented study are studied 
groups restricted to the Polish population, lack of as-
sessment of DM metabolic control, not fully collected 
patient data, and the omission of patient educational 
level. Data on the percentage of foot ulcers recurrences 
and small amputations were not collected. 
The presented study proved the existence of specific 
risk factors for DF of neuropathic origin occurrence in 
patients with type 2 DM. The explanation of men’s pre-
disposition to DF of neuropathic origin development is 
their susceptibility to develop neuropathy. This fact has 
been proved in other studies and observed in clinical 
practice. The impact of male gender as a risk factor of 
neuropathy in patients with DM was demonstrated in 
other studies [12, 20, 28]. The presented study showed 
that male gender was also a factor increasing the risk of 
DF of neuropathic origin in type 2 DM population. This 
may result from poorer hygiene in men than in women. 
The impact of patients’ height may be interpreted with 
the positive correlation between peripheral nerves 
length and the neuropathy occurrence. The influence 
of weight may be the effect of higher pressure on the 
foot area in overweight patients. Patients with higher 
BMI have increased load for foot tissue. 
The most similar study was performed by Fargol 
et al. [12]. That study included 55 patients with DF of 
neuropathic origin and 55 with type 2 DM without DF. 
Fargol et al. showed the following factors increased the 
risk of DF development: patient’s age, female gender, 
total cholesterol concentration, DM duration and three 
or more (per eight possible) points in the Michigan 
Neuropathic Diabetic Scoring. 
Figure 1. Gender structure in study and control groups 
(percentage) 
Rycina 1. Struktura płci w grupach badanej i kontrolnej (odsetek)
Table III. Results of univariate logistic regression analysis
Tabela III. Wyniki jednoczynnikowej analizy regresji 
logistycznej
Predictors Odds ratio 95% confidence  
interval
p value
Male gender 6.63 3.31–13.27 0.00001
Type 2 diabetes duration 1.10 1.06–1.14 0.00001
Height 1.09 1.06–1.13 0.00001
Weight 1.04 1.04–1.06 0.00001
Waist circumference 1.05 1.02–1.08 0.001
Figure 2. Percentage of complications in studied groups for 
variables presenting statistically significant difference
Rycina 2. Odsetek powikłań w badanych grupach dla zmiennych 
istotnych statystycznie
14
PR
A
C
E 
O
RY
G
IN
A
LN
E
Risk factors of diabetic foot of neuropathic origin  Piotr Nehring et al.
In the presented study, there is no confirmation of 
the influence of higher age and female gender on DF 
frequency. Moreover, in the presented study, female 
gender decreased the odds of DF of neuropathic origin 
development. However, the presented study confirms 
the impact of DM duration on DF prevalence. All patients 
were assessed on the Toronto Clinical Neuropathy Scale 
as six or more points, and that itself was a factor increasing 
the risk of complications of neuropathy [25]. 
Another similar study was performed by Bennett et 
al. on 77 individuals (27 with DF of neuropathic origin 
and 50 with type 2 DM without DF and/or neuropathy) 
[17]. In that study, cases and controls were matched 
with sex structure and age. The following risk factors of 
DF of neuropathic origin were demonstrated: increased 
blood pressure in foot arteries and decreased ankle 
joints mobility. There were also a positive correlation 
between HbA1C value and DF frequency observed in 
the study group. The impact of DM duration or BMI 
value was not demonstrated. 
There have been several studies on the risk factors 
of neuropathy development in patients with DM. The 
multicentre Tesfaye et al. study conducted in 1996 on 3,250 
patients demonstrated that the risk factors of neuropathy 
development in diabetic population were: age, DM dura-
tion, metabolic control, height, proliferative retinopathy 
presence, tobacco use, HDL concentration and coronary 
heart failure presence [16]. In the presented study, some of 
the abovementioned factors were identified as important 
in DF of neuropathic origin development.
The Barbosa et al. study showed that a history of 
thrombotic episodes increased the risk of neuropathy 
occurrence in patients with DM [21]. The presented 
study did not confirm the impact of the history of 
thrombotic episodes on the odds of DF of neuropathic 
origin frequency. 
Conclusion 
The identification of specific factors increasing the risk 
of DF of neuropathic origin in patients with type 2 DM 
is important due to the implications for a clinician who 
classifies patients to risk groups. A patient’s classifica-
tion to the high risk group of DF development may be 
performed using simple anthropometric measurements 
without additional tests. The aim of high risk group 
identification is to increase clinician awareness and care, 
and in consequence avoid not only DF of neuropathic 
origin occurrence, but also protect against other com-
plications, especially lower limb amputation.
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